Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Cheng Lab, Suzhou Institute of Systems Medicine, Suzhou, China.
Front Immunol. 2021 Jan 8;11:602395. doi: 10.3389/fimmu.2020.602395. eCollection 2020.
The widespread prevalence of coronavirus disease-2019 (COVID-19) which is caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has resulted in a severe global public health emergency. However, there are no sensitive biomarkers to predict the disease prognosis of COVID-19 patients. Here, we have identified interleukin-8 (IL-8) as a biomarker candidate to predict different disease severity and prognosis of COVID-19 patients. While serum IL-6 become obviously elevated in severe COVID-19 patients, serum IL-8 was easily detectible in COVID-19 patients with mild syndromes. Furthermore, lL-8 levels correlated better than IL-6 levels with the overall clinical disease scores at different stages of the same COVID-19 patients. Thus, our studies suggest that IL-6 and IL-8 can be respectively used as biomarkers for severe COVID-19 patients and for COVID-19 disease prognosis.
由严重呼吸综合征冠状病毒 2（SARS-CoV-2）感染引起的 2019 年冠状病毒病（COVID-19）广泛流行，导致了严重的全球公共卫生紧急情况。然而，目前尚无敏感的生物标志物可预测 COVID-19 患者的疾病预后。在这里，我们已将白细胞介素-8（IL-8）鉴定为预测 COVID-19 患者不同疾病严重程度和预后的候选生物标志物。虽然严重 COVID-19 患者的血清 IL-6 明显升高，但轻度综合征的 COVID-19 患者中很容易检测到血清 IL-8。此外，IL-8 水平与同一 COVID-19 患者不同阶段的总体临床疾病评分的相关性优于 IL-6 水平。因此，我们的研究表明，IL-6 和 IL-8 可分别用于严重 COVID-19 患者和 COVID-19 疾病预后的生物标志物。
